Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...
Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...
"EGFR Inhibitors-Induced Skin Disorders Market Report 2034"In 2023, there were more than 30,000 treatable incident cases of EGFR inhibitors in the United States. DelveInsight's“EGFR Inhibitors-Induced ...
Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...
TKIs under active clinical investigation are mostly derived from quinazoline, and are low molecular weight synthetic molecules that block the magnesium-ATP-binding pocket of the intracellular tyrosine ...
EGFR™ inhibitor, demonstrates preliminary anti-tumor activity across a variety of advanced EGFR-mutant non-small cell lung ...
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor ...
(MENAFN- GetNews) The Key EGFR Inhibitor Companies in the market include - Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others. DelveInsight's “EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback